Observational studyColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
Indocyanine green-guided robotic-assisted mesorectal lymphadenectomy for high-risk T1 rectal carcinoma: Preliminary results of a prospective cohort study (IDEAL stage 2a).
Observational study in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimLymph node metastases occur in 10%-15% of high-risk T1 rectal tumours. Total mesorectal excision remains the standard treatment, whereas chemoradiotherapy is reserved for patients with frailty. Indocyanine green (ICG)-guided lymphadenectomy may represent an organ-preserving alternative for patients at high risk of node metastasis.
methodsFrom May 2021 to July 2025, 11 patients underwent curative transanal excision surgery for early-stage low rectal cancer that was classified as high-risk pT1 adenocarcinoma. ICG (1 mg) was injected submucosally to label all lymph nodes irrespective of their metastatic status. ICG-guided robotic-assisted mesorectal lymphadenectomy was performed with the Firefly Imaging System (INTUITIVE©).
resultsInitially, ICG was injected intraoperatively (n = 2 patients). However, due to unsuccessful mapping in the second patient, ICG was then administered the day before surgery in all subsequent patients, resulting in successful visualisation and excision. Lymphatic drainage was not along the superior rectal artery in two patients. Lymphadenectomy was mainly performed along the superior rectal artery to its bifurcation into the right and left rectal arteries in the mid-rectum. The median number of excised lymph nodes was 16.7 (range: 9-29). Lymph node invasion was detected in one patient who then received adjuvant chemotherapy. The median hospital stay was 2 days, without complications. After 36 months of follow-up (range: 12-60), all patients were alive without disease progression or functional impairment.
conclusionIn patients with early T1 rectal tumours, ICG-guided robotic-assisted mesorectal lymphadenectomy seems to be technically feasible. These preliminary results, feasibility and oncological safety need to be confirmed in a prospective multicentre trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.